Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021
May 13, 2021 08:00 ET | Beyond Air™
Interim analysis from the ongoing, open-label, randomized acute viral pneumonia (including COVID-19) pilot study shows 150 ppm nitric oxide (NO) administered with LungFit® PRO is well-tolerated with...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Appoints Peter Senior as Director of Business Development
May 03, 2021 08:00 ET | Beyond Air™
GARDEN CITY, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in May 2021
April 14, 2021 08:00 ET | Beyond Air™
GARDEN CITY, N.Y., April 14, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® to Present Abstracts at the American Thoracic Society Virtual Sessions in May 2021
March 24, 2021 08:00 ET | Beyond Air™
GARDEN CITY, N.Y., March 24, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric NO for the...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in March 2021
March 01, 2021 08:00 ET | Beyond Air™
GARDEN CITY, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease
February 16, 2021 08:00 ET | Beyond Air™
Award will help fund the development of high concentration nitric oxide (NO) for Nontuberculous Mycobacteria (NTM) pulmonary disease, which disproportionately affects cystic fibrosis (CF) patients ...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update
February 09, 2021 16:05 ET | Beyond Air™
U.S. FDA reviewing premarket approval (PMA) submission for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), as Company prepares for commercialization Interim results...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast
January 15, 2021 16:10 ET | Beyond Air™
GARDEN CITY, N.Y., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Initiates Patient Screening for LungFit™ GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease
December 07, 2020 08:00 ET | Beyond Air™
Expect to dose first patient in January 2021 and report interim data mid-2021 Success in nontuberculous mycobacteria (NTM) at-home study paves the way to enter the much broader market treating severe...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® to Participate in the 32nd Annual Piper Sandler Healthcare Conference from December 1-3, 2020
November 19, 2020 08:00 ET | Beyond Air™
GARDEN CITY, N.Y., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...